Teva Pharma Industries Stock Today
| TEVA Stock | USD 16.10 0.14 0.86% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Teva Pharma is trading at 16.10 as of the 22nd of March 2025, a 0.86% down since the beginning of the trading day. The stock's open price was 16.24. Teva Pharma has about a 43 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of March 1990 | Category Healthcare | Classification Health Care |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel. The company has 1.15 B outstanding shares of which 27.81 M shares are at this time shorted by private and institutional investors with about 1.85 trading days to cover. More on Teva Pharma Industries
Moving together with Teva Stock
Moving against Teva Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Teva Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Richard Francis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, Tel Aviv 35, ARCA Pharmaceutical, BETTERINVESTING 100 INDEX, Israel Wall Street, Adviser Favorites, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal TestingCatholic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTeva Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Teva Pharma's financial leverage. It provides some insight into what part of Teva Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Teva Pharma Industries (TEVA) is traded on New York Stock Exchange in USA. It is located in 124 Dvora HaNevi?a St., Tel Aviv, Israel, 6944020 and employs 33,892 people. Teva Pharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 18.65 B. Teva Pharma Industries conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 1.15 B outstanding shares of which 27.81 M shares are at this time shorted by private and institutional investors with about 1.85 trading days to cover.
Teva Pharma Industries currently holds about 2.22 B in cash with 1.25 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.0.
Check Teva Pharma Probability Of Bankruptcy
Ownership AllocationTeva Pharma Industries shows a total of 1.15 Billion outstanding shares. Over half of Teva Pharma's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Teva Ownership Details
Teva Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Pointstate Capital Lp | 2024-12-31 | 13.5 M | |
| Geode Capital Management, Llc | 2024-12-31 | 9.3 M | |
| Australiansuper Pty Ltd | 2024-12-31 | 9.2 M | |
| Duquesne Family Office Llc | 2024-12-31 | 9 M | |
| Slate Path Capital Lp | 2024-12-31 | 8.5 M | |
| Glenview Capital Management Llc | 2024-12-31 | 8.5 M | |
| Arrowstreet Capital Limited Partnership | 2024-12-31 | 7 M | |
| Renaissance Technologies Corp | 2024-12-31 | 7 M | |
| Hhg Plc | 2024-12-31 | 6.7 M | |
| Fmr Inc | 2024-12-31 | 82 M | |
| Blackrock Inc | 2024-12-31 | 50.6 M |
Teva Pharma Historical Income Statement
Teva Stock Against Markets
Teva Pharma Corporate Directors
| Nechemia Peres | Independent Director | Profile | |
| JeanMichel Halfon | Statutory - independent director | Profile | |
| Perry Nisen | Independent Director | Profile | |
| Gerald Lieberman | Independent Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (1.45) | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.